Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-4082 Formulation 1 · 1 trial · 1 indication
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| Panel A Sequence 1 | EXPERIMENTAL | Participants will be administered daily oral doses of MK-4082 formulation 1 (F1) and MK-4082 formulation 2 (F2) in a fixed sequence over the first 4 weeks, with only one formulation administered on any given day. In week 5, participants will be administered daily oral doses of MK-4082 F2 for 7 days followed by daily oral doses of MK-4082 F1 for 7 days. |
| Panel A Sequence 2 | EXPERIMENTAL | Participants will be administered daily oral doses of MK-4082 F1 and MK-4082 F2 in a fixed sequence over the first 4 weeks, with only one formulation administered on any given day. In week 5, participants will be administered daily oral doses of MK-4082 F1 for 7 days followed by daily oral doses of MK-4082 F2 for 7 days. |
| Panel B Sequence 1 | EXPERIMENTAL | Participants will be administered daily oral doses of MK-4082 F1 and MK-4082 formulation 4 (F4) in a fixed sequence over the first 4 weeks, with only one formulation administered on any given day. In week 5, participants will be administered daily oral doses of MK-4082 F4 for 7 days followed by daily oral doses of MK-4082 F1 for 7 days. |
| Panel B Sequence 2 | EXPERIMENTAL | Participants will be administered daily oral doses of MK-4082 F1 and MK-4082 F4 in a fixed sequence over the first 4 weeks, with only one formulation administered on any given day. In week 5, participants will be administered daily oral doses of MK-4082 F1 for 7 days followed by daily oral doses of MK-4082 F4 for 7 days. |
| Name | Type | Description |
|---|---|---|
| MK-4082 Formulation 1 (F1) | DRUG | Oral Tablet |
| MK-4082 Formulation 2 (F2) | DRUG | Oral Tablet |
| MK-4082 Formulation 4 (F4) | DRUG | Oral Tablet |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has a body mass index (BMI) between 25 and 40 kg/m\^2, inclusive and weighs at least 60 kg Exclusion Criteria: The main exclusion criteria include but are not limited to the follow...
MK-4082 Formulation 1 is an investigational small molecule being studied in healthy overweight and obese participants. It is currently in Phase 1 clinical development and is not approved by the FDA. The drug is being evaluated in a clinical trial to assess multiple formulations of MK-4082.
MK-4082 Formulation 1 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting a Phase 1 clinical trial to evaluate this investigational small molecule in healthy participants.
MK-4082 Formulation 1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is designed to study multiple formulations of MK-4082 in healthy overweight and obese participants.
MK-4082 Formulation 1 is being studied in clinical trial NCT07748351, titled 'A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)'. This Phase 1 trial is not yet recruiting and plans to enroll 48 participants in the United States.
MK-4082 Formulation 1 is one of multiple formulations of the investigational drug MK-4082 being studied in clinical trials. The Phase 1 trial NCT07748351 is designed to evaluate these different formulations in healthy overweight and obese participants.